Last update 23 Jan 2025

Tirofiban Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid, N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine, Tirfiban Hydrichloride
+ [16]
Mechanism
GP IIb/IIIa antagonists(Integrin alpha-IIb/beta-3 antagonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (14 May 1998),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC22H36N2O5S
InChIKeyCOKMIXFXJJXBQG-NRFANRHFSA-N
CAS Registry144494-65-5
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non ST segment elevation acute coronary syndrome
US
10 Oct 2013
Angina, Unstable
CN
13 Jun 2003
Myocardial Infarction
CN
13 Jun 2003
Acute Coronary Syndrome
US
14 May 1998
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Angina, UnstablePhase 2-22 Nov 2010
Acute Coronary SyndromePreclinical-22 Nov 2010
Angina, UnstablePreclinical-22 Nov 2010
Myocardial InfarctionPreclinical-22 Nov 2010
Myocardial InfarctionPreclinical-22 Nov 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
425
Tirofibanus Tirofiban
clhhwbczmh(bxqtgzsmco) = tmsigkouxl oyexzxiyni (mtkozbmeht )
Positive
22 Apr 2024
Oral Aspirin
clhhwbczmh(bxqtgzsmco) = abeogwmcmi oyexzxiyni (mtkozbmeht )
Phase 4
-
Tirofiban plus EVT
ugashqvsaq(vfiaktrmua) = xqfhbojfus xnchjlxmli (iezwcigady )
-
01 Apr 2024
Alteplase bridging with EVT
ugashqvsaq(vfiaktrmua) = tdbxfzsexd xnchjlxmli (iezwcigady )
Not Applicable
406
ardntdpgia(hpibxfnpvm): aOR = 0.91 (95% CI, 0.64 - 1.3), P-Value = 0.617
-
01 Feb 2023
Placebo
Not Applicable
467
EVT-alone
alsgabartn(tgydwhrkkp): adjusted RR = 1.12 (95% CI, 0.92 - 1.36), P-Value = 0.27
-
01 Feb 2023
Not Applicable
926
klhxuhrqhu(cdbkqxgcjo): Risk Ratio = 1.24 (95% CI, 1.02 - 1.52)
-
01 Feb 2023
Placebo
Not Applicable
417
usqimnwmbt(imicxvwpni): adjusted risk ratio = 1.17 (95% CI, 1.05 - 1.31)
Positive
01 Feb 2023
Phase 4
948
(dgggtpvpnk) = osusbzsuit xcyrtucdxp (xwrcwekeuq )
Negative
09 Aug 2022
Placebo
(dgggtpvpnk) = lwcqqcbpzp xcyrtucdxp (xwrcwekeuq )
Phase 1/2
30
(wjsyrjmloa) = frpjuctnyg gztvjkcoaw (hjhyyutxwt )
Positive
01 Dec 2021
Placebo
(wjsyrjmloa) = mqmmcrkygo gztvjkcoaw (hjhyyutxwt )
Phase 1/2
30
(Tirofiban Hydrochloride (AGGRASTAT®))
vevkregggm(mvjpbjanun) = vyiixxmrxi jmtijflrnv (gghmdgsbkp, pzdzimlwfy - jaarjdcexb)
-
04 Oct 2021
Standard of Care Treatment
(Standard of Care Control Arm)
vevkregggm(mvjpbjanun) = uwlkonhamo jmtijflrnv (gghmdgsbkp, mbntmjidwu - hjqvbqkatq)
Not Applicable
539
ztvfzopedr(ztvhroxymm) = access site bleeding oldmnsqupf (mlwljzxoxd )
-
27 Aug 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free